Kidney patients who happened to be getting high-dose Calcitriol were 9X less likely to die of COVID-19

Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-based Study

preprints.org > life sciences > biochemistry > doi: 10.20944/preprints202104.0173.v1

Joaquim Oristrell * ORCID logo , Joan C. Oliva , Isaac Subirana , Enrique Casado , Didier Dominguez , Andrea Toloba , Patricia Aguilera , Joan Esplugues , Pilar Fafian , Maria Grau *

Calcitriol, the fully activated form of Vitamin D, is typically only available by prescription. This study only has statistics for Yes/No, taking any amount of Calcitriol. The charts appear to indicate death rates when COVID-19 came to the region. It appears that there was an increased death rate of 9X for low vs high Calcitriol ( 0.18 / 0.02) No indication of death rate for zero vs high Calcitriol Suspect that the Calcitriol was given daily --- 1. Overview Kidney and vitamin D contains the following summary {include} --- 1. Getting Vitamin D into your blood and cells has the following chart * Active vitamin D (calcitriol) might fight COVID-19 – Jan 5, 2021 * Kidney failure – still debating what form of vitamin D to use – April 2016 * 26 health factors increase the risk of COVID-19 – all are proxies for low vitamin D CDC * Chronic Kidney Disease is one of the factors for increased COVID-19 risk * 9X COVID-19 survival in nursing home if had 80,000 IU dose of vitamin D in previous month – Oct 2020 * Nursing home residents who happened to be taking Vitamin d were 9X less likely to die of COVID-19 * very similar to the Kidney study on this page

📄 Download the PDF from VitaminDWiki

Treatment with calcitriol, the hormonal form of vitamin D, has shown beneficial effects in ex-perimental models of acute lung injury. In this study we aimed to analyze the associations be-tween calcitriol supplementation and the risk of SARS-CoV2 infection or COVID-19 mortality. Individuals ≥18 years old living in Catalonia and supplemented with calcitriol from April 2019 to February 2020 were compared with propensity score matched controls. Outcome variables were SARS-CoV2 infection, severe COVID-19 and COVID-19 mortality. Associations between calcitriol supplementation and outcome variables were analyzed using multivariable Cox proportional regression. A total of 8076 patients were identified as being on calcitriol treatment. Advanced chronic kidney disease and hypoparathyroidism were the most frequent reasons for calcitriol supplementation in our population.

Calcitriol use was associated with reduced risk of SARS-CoV2 infection (HR 0.78 [CI 95% 0.64-0.94], p=0.010), reduced risk of severe COVID-19 and reduced COVID-19 mortality (HR 0.57 (CI 95% 0.41-0.80), p=0.001) in patients with advanced chronic kidney disease. In addition, an inverse association between mean daily calcitriol dose and COVID-19 severity or mortality was observed in treated patients, independently of renal function. Our findings point out that patients with advanced chronic kidney disease could benefit from calcitriol supplementation during the COVID-19 pandemic.

Title change made April 12, 2021 caused the visitor count to reset.
There have actually been visitors to this page since it was originally made